A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 25 Jul 2023 Planned primary completion date changed from 31 May 2026 to 30 May 2029.
- 05 Jul 2022 Planned End Date changed from 15 Nov 2024 to 30 May 2029.
- 05 Jul 2022 Planned primary completion date changed from 31 May 2024 to 31 May 2026.